A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT05119335

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05119335. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.

Study identification

NCT ID: NCT05119335
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

Interventions

Oral NKT2152 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 26, 2021 (Actual)
Primary completion: Aug 22, 2025 (Actual)
Completion: Sep 30, 2025 (Actual)
Last update posted: Nov 12, 2025

2021 – 2025

United States locations

U.S. sites: 13
U.S. states: 13
U.S. cities: 13

Facility	City	State	ZIP	Site status
HonorHealth	Scottsdale	Arizona	85258	—
UCLA	Los Angeles	California	90095	—
Sarah Cannon Research Institute	Denver	Colorado	80218	—
Emory University	Atlanta	Georgia	30322	—
Indiana University Simon Comprehensive Cancer Center	Indianapolis	Indiana	46202	—
University of Iowa	Iowa City	Iowa	52242	—
National Cancer Institute	Bethesda	Maryland	20892-9760	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Nebraska Cancer Specialists	Omaha	Nebraska	68130	—
University of Oklahoma	Oklahoma City	Oklahoma	73117	—
Oregon Health and Science University	Portland	Oregon	97239	—
MD Anderson Cancer Center	Houston	Texas	77030	—
Seattle Cancer Care Alliance	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05119335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2025 · Synced Nov 13, 2026